drugset / Trial / NCT05034497
Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
NaSequentialOpen-labelTreatment
Summary
This is an open-label Phase I clinical study that will administer a single dose of 186RNL via intraventricular catheter for treatment of Leptomeningeal Metastases (LM).
Timeline
- Start
- 2021-12-06
- Primary completion
- 2025-12-21
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 186RNL | Other / unclassified | 5 ml | Other |